Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to estimate the effectiveness of 2 doses of Rotarix™ vaccination in preventing rotavirus severe gastroenteritis among children hospitalized in Belem area, Brazil.
The study will be comprised of two parts: Case-control study and Rotavirus strain surveillance.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Gastroenteritis cohort | Children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis |
| |
| Hospital control cohort | Children hospitalized for non gastroenteritis causes | ||
| Neighbourhood control cohort | Children without any symptoms of gastroenteritis or severe gastroenteritis |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stool sampling | Procedure | Stool samples collected and checked for the presence of rotavirus |
|
| Measure | Description | Time Frame |
|---|---|---|
| Risk of Enzyme Linked Immunosorbent Assay (ELISA) confirmed rotavirus severe gastroenteritis in children fully vaccinated with Rotarix™, compared to risk of ELISA confirmed rotavirus severe gastroenteritis in unvaccinated children | Average time frame: 12-24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Risk of ELISA confirmed rotavirus severe gastroenteritis in children vaccinated with at least one dose of Rotarix™, compared to risk of ELISA confirmed rotavirus severe gastroenteritis in unvaccinated children | Average time frame: 12-24 months | |
| Occurrence of severe gastroenteritis among children admitted to study clinics/hospitals for severe gastroenteritis |
Not provided
Inclusion Criteria:
For cases:
For controls:
Exclusion Criteria:
For cases:
For controls:
Not provided
Not provided
Not provided
Gastroenteritis Cohort: Cases will include children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis the study clinics/hospitals, during the designated study period, Hospital control cohort: Children hospitalized for non gastroenteritis causes, Neighbourhood control cohort: Children without any symptoms of gastroenteritis or severe gastroenteritis.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Belém | Pará | 66 090 000 | Brazil |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21150692 | Background | Justino MC, Linhares AC, Lanzieri TM, Miranda Y, Mascarenhas JD, Abreu E, Guerra SF, Oliveira AS, da Silva VB, Sanchez N, Meyer N, Shafi F, Ortega-Barria E, Soriano-Gabarro M, Colindres RE. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belem, Brazil. Pediatr Infect Dis J. 2011 May;30(5):396-401. doi: 10.1097/INF.0b013e3182055cc2. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Stool sample
| Average time frame: 12-24 months |
| Occurrence of rotavirus serotypes among children | Average time frame: 36 months |